Alector launches Onglyza and Komboglyze
Date: 11 Jun 2014

Following the acquisition by AstraZeneca of the entirety of Bristol-Myers Squibb’s interests in the two companies’ diabetes alliance, Alector Pharmaceuticals is launching two products for type 2 diabetes mellitus.

Onglyza (saxagliptin) is an oral dipeptidyl peptidase 4 (DPP-4) inhibitor.
For more information about Onglyza click here.

Komboglyze combines saxagliptin and metformin.
For more information about Komboglyze click here.